Date:6/11/2008

her development or commercialization of the underlying technology, and that the Company may not be able to protect its trade secrets or other confidential proprietary information; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; uncertainty as to availability of raw materials, and in particular, cGMP grade materials, on acceptable terms or at all; the risk that the Company's license optionee for Topical Interferon Alpha-2b may not continue to provide the Company with interferon alpha-2b or exercise its option, which would have a material adverse effect on the drug's further development and commercialization; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, including its latest Annual Information Form, at http://www.sedar.com, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the beliefs, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, opinions or expectations, or other circumstances change, except as required by law.

'/>"/>

SOURCE Helix BioPharma Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
2. Helix BioPharma reports Q2 2008 highlights, financial results
3. Helix BioPharma shareholders vote in favour of management
4. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
5. Helix BioPharma closes $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma announces $16.9 million private placement of common shares
8. Helix BioPharma Corp. announces management changes
9. Helix BioPharma Corp. announces fiscal 2007 results
10. Helix BioPharma Chairman resigns
11. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor